Keros Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical inflection point, having traded breadth for depth. The successful transition of elritercept to Takeda has provided a temporary financial fortress, but the ultimate value of the company now rests on binary clinical outcomes for rinvatercept. Investors are essentially weighing a lean, de-risked operational model against the inherent volatility of early-stage clinical trials. The core tension for shareholders is whether the current cash position is a genuine bridge to 2028 or a temporary cushion that will be rapidly consumed by upcoming trial costs. While the reduction in operating expenses is a positive signal of management discipline, the lack of recurring revenue makes Keros a high-beta play on its TGF-β platform's ability to deliver disease-modifying results in neuromuscular markets.